Andrew J. Fromkin - Dec 1, 2023 Form 4 Insider Report for Immunovant, Inc. (IMVT)

Role
Director
Signature
/s/ Eva Renee Barnett, attorney-in-fact for Andrew J. Fromkin
Stock symbol
IMVT
Transactions as of
Dec 1, 2023
Transactions value $
-$490,697
Form type
4
Date filed
12/5/2023, 04:30 PM
Previous filing
Apr 14, 2023
Next filing
Apr 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMVT Common Stock Sale -$153K -3.94K -3.9% $38.78 97.1K Dec 1, 2023 Direct F1, F2
transaction IMVT Common Stock Sale -$145K -3.64K -3.75% $39.81 93.4K Dec 1, 2023 Direct F1, F3
transaction IMVT Common Stock Sale -$193K -4.77K -5.11% $40.46 88.7K Dec 1, 2023 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan adopted on May 24, 2023, in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of the above award of restricted stock covering shares of common stock and does not represent a discretionary sale by the reporting person.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.19 - $39.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $39.22 - $40.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
F4 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $40.24 - $40.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.